Category Archives: Patent Eligible Subject Matter

October 2019 Update: Subject Matter Eligibility – A Closer Look

Posted on October 30, 2019 by Edward Sandor

Guest post from Edward Sandor. Warren Woessner also posted a blog about the Updated Guidance on October 21. On October 17, 2019, the USPTO published an October 2019 Patent Eligibility Guidance Update to the earlier 2019 Revised Patent Subject Matter … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

PTO Releases New Guidelines on Subject Matter Eligibility

Posted on October 21, 2019 by Warren Woessner

On Oct. 17th, the PTO published Guidelines intended to supplement the Jan. 2019 Subject Matter Eligibility Guidelines (“2019 PEG”). The Guidelines and associated Examples are extensive. Only two of the Examples (43 and 44) are concerned with the life sciences. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Athena’s “Questionable” Petition for Cert.

Posted on October 8, 2019 by Warren Woessner

On October 1st, Athena filed a petition for a writ of certiorari to the Supreme Court following the Fed. Cir.’s fractured denial for its petition for rehearing en banc in Amgen v. Mayo. The original request for rehearing en banc … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

INO v. Praxair – Method-by-Selection Claims Fail Mayo/Alice Test

Posted on September 3, 2019 by Warren Woessner

In Ino Therapeutics LLC v. Praxair Distrib., Inc., Appeal no.2018-1019 (Fed. Cir., August 27, 2019) a divided Fed. Cir. panel comprising Judges Dyk and Prost, Newman dissenting affirmed a district court decision that a number of INO’s patent claims were … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment